XO Life’s brite™ platform: Digital therapy support for people with cystic fibrosis
August 14, 2025

Munich, Germany, July 24, 2025 — Vertex Pharmaceuticals, a US pharmaceutical company focused on serious diseases such as cystic fibrosis, beta thalassemia, and sickle cell disease, and XO Life, a leading digital health scaleup, announced their collaboration on digital therapy support for people with cystic fibrosis. At its center is a new area on the brite™ platform, available on the web or as an app, aimed at patients receiving treatment for cystic fibrosis (CF). After being informed by their doctor and registering free of charge, patients can digitally accompany and document their therapy and inform themselves with medically validated content. The platform enables structured recording of use and provides personalized insights.
What is cystic fibrosis?
Cystic fibrosis: One of the most common rare and genetic diseases in Europe Cystic fibrosis (CF), also known as mucoviscidosis, is one of the most common rare, genetic, and life-shortening diseases in Europe. Cystic fibrosis is caused by a defective or missing CFTR protein resulting from mutations in the CFTR gene.1 Some of these mutations result in too little or dysfunctional CFTR protein being present in the cell membrane. Due to the defective or missing CFTR protein, the exchange of salt and water in the cells of various organs, including the lungs, is impaired. As a result, the secretions of vital glands as well as the mucus in the lungs become thick and sticky, impairing the function of various organs. In the airways, the thick mucus can cause chronic lung infections and progressive lung damage.
Digital therapy support for people with cystic fibrosis
The cystic fibrosis therapy area within the brite™ platform provides medically reviewed content, including on administration, as well as features such as intake reminders and logging. It is offered as an additional service and can be used web-based or via an app for iOS and Android.
brite™ platform: Digital interface for therapy transparency
“Continuously accompanying the course of therapy and documenting it transparently is especially important in rare diseases. Experiences from everyday care, known as real-world data, can help to gain a better understanding of how the disease actually progresses in everyday life. The brite™ platform makes it possible to provide relevant information in a clear way and thus create more transparency for everyone involved,” says Dr. Friderike Bruchmann, Co-Founder & CEO of XO Life. The brite™ platform does not replace medical advice but offers supplementary, easy-to-understand, verified information and digital support for therapy. Optionally, users can share their data with their treatment team to make it easier to monitor the course of therapy.
About XO Life
XO Life has created a globally unique meta-platform, the brite™ platform, for digital product and therapy support for patients. While using a product or undergoing therapy, patients are accompanied with verified medical and health-related content, record their health and therapy progress, receive personalized insights and medical support from specialists, and can exchange experiences with other patients. Manufacturers can license their own product and therapy areas on the brite™ platform and make them available to their patients with their own branding, content, questions, and services. Through personalized information and continuous support during therapy, manufacturers make an important contribution to therapy success, adherence, and safe use for patients.
XO Life is regarded as one of the great hopes in healthcare and is one of the leading digital health scaleups in Germany and Europe. XO Life is the market leader in Germany and works with global market leaders, German mid-sized pharmaceutical companies, and orphan drug manufacturers. The brite™ platform has recently become available in all European countries and languages.
Further links
Website: www.britehealth.com
LinkedIn: https://www.linkedin.com/company/xo-life
YouTube: https://www.youtube.com/@xo-life/featured
Sources:
1.CFSource. Ursache der Mukoviszidose. Available online at: https://www.cfsource.de/de/mukoviszidose/ursache, last accessed: June 2023.
2.CFSource. Ursache der Mukoviszidose. Available online at: https://www.cfsource.de/de/mukoviszidose/ursache, last accessed: June 2023.
3.CFSource. Symptome bei Mukoviszidose. Available online at: https://www.cfsource.de/de/mukoviszidose/symptome, last accessed: June 2023.
XO Life press contact
XO Life GmbH
Dr. med. Lisa M. Köhler
Head of Medical Affairs & Pharmacovigilance
Agnes-Pockels-Bogen 1
80992 München
Email: pr@xo-life.com

